ACA Looks 46.2% Overvalued on GF Value™ Amid CRH Acquisition App
Arcosa Inc (ACA) shareholders approved its acquisition by CRH for $150 per share, pending regulatory approval. ACA's stock is 46.2% overvalued per GF Value™ at $145.45 vs. intrinsic value of $99.52. CRH's acquisition is expected to close in Q1 2027. ACA's GF Score™ is 76/100, with strong momentum and profitability but weak valuation. 9 gurus hold ACA, with 8 adding positions.
How this was made
The 30-second read
Why it matters
The acquisition finalizes CRH's expansion in infrastructure, while ACA's stock is already priced near the deal value, limiting immediate trading opportunities.
Market read
Primary M&A disclosure for a mid‑cap US stock; modest impact on broader markets.
What to watch
Regulatory approval risk and integration costs could affect CRH's long‑term returns.
Background
Arcosa Inc (NYSE: ACA) operates in construction products and announced a cash acquisition by CRH at $150 per share after shareholder approval.
Ticker impact
Shareholders approved CRH's all‑cash $150 per share acquisition of Arcosa Inc.
Minor upside if closing premium exceeds market price; otherwise flat.
Acquisition terms were disclosed for the first time; price already reflects premium.
Market effects
Industrial sector may see modest consolidation as CRH adds construction products.
European industrial stocks could benefit from perceived M&A activity.
Limited; primarily affects US‑listed ACA and European‑listed CRH.
Counterpoint
Deal price may be too low if synergies are overestimated; ACA shareholders could push for higher premium.
Key entities
- companyArcosa Inc
US‑listed industrial firm targeted by the acquisition.
- companyCRH plc
European building materials group acquiring ACA.
